|
NEU1 |
neuraminidase 1 |
- Sialic acid metabolism
- Defective NEU1 causes sialidosis
- Neutrophil degranulation
- Glycosphingolipid catabolism
|
- Oseltamivir
- Celecoxib
- Acetylsalicylic acid
|
- Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
- Sialidosis; Mucolipidosis I
- Galactosialidosis
|
|
NINJ1 |
ninjurin 1 |
|
|
|
|
NINJ2 |
ninjurin 2 |
|
|
|
|
NKG7 |
natural killer cell granule protein 7 |
|
|
|
|
NUP62 |
nucleoporin 62 |
- ISG15 antiviral mechanism
- Transport of the SLBP independent Mature mRNA
- Transport of the SLBP Dependant Mature mRNA
- Transport of Mature mRNA Derived from an Intronless Transcript
- Transport of Mature mRNA derived from an Intron-Containing Transcript
- Rev-mediated nuclear export of HIV RNA
- Transport of Ribonucleoproteins into the Host Nucleus
- NS1 Mediated Effects on Host Pathways
- Viral Messenger RNA Synthesis
- NEP/NS2 Interacts with the Cellular Export Machinery
- Regulation of Glucokinase by Glucokinase Regulatory Protein
- Nuclear import of Rev protein
- Vpr-mediated nuclear import of PICs
- IPs transport between nucleus and cytosol
- IP3 and IP4 transport between cytosol and nucleus
- IP6 and IP7 transport between cytosol and nucleus
- snRNP Assembly
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of ubiquitinylation proteins
- Nuclear Pore Complex (NPC) Disassembly
- Regulation of HSF1-mediated heat shock response
- SUMOylation of SUMOylation proteins
- SUMOylation of chromatin organization proteins
- SUMOylation of RNA binding proteins
- SUMOylation of DNA replication proteins
- SUMOylation of DNA replication proteins
- Transcriptional regulation by small RNAs
- Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)
- tRNA processing in the nucleus
- HCMV Early Events
- HCMV Late Events
- Postmitotic nuclear pore complex (NPC) reformation
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
|
|
|
|
OAZ1 |
ornithine decarboxylase antizyme 1 |
- Regulation of ornithine decarboxylase (ODC)
- Metabolism of polyamines
|
|
|
|
OR10AG1 |
olfactory receptor family 10 subfamily AG member 1 |
- Expression and translocation of olfactory receptors
|
|
|
|
OSGEP |
O-sialoglycoprotein endopeptidase |
- tRNA modification in the nucleus and cytosol
|
|
|
|
PAQR6 |
progestin and adipoQ receptor family member 6 |
|
|
|
|
PKLR |
pyruvate kinase L/R |
|
- Pyruvic acid
- 2-Phosphoglycolic Acid
- beta-D-fructofuranose 1,6-bisphosphate
- Mitapivat
|
- Pyruvate kinase (PK) deficiency, including: Red cell pyruvate kinase (PK) deficiency; Pyruvate kinase hyperactivity
|
|
PLN |
phospholamban |
- Ion homeostasis
- Ion transport by P-type ATPases
|
|
|
|
PLP1 |
proteolipid protein 1 |
|
|
- Hypomyelinating leukodystrophy (HLD); Pelizaeus-Merzbacher disease (PMD)
- Hereditary spastic paraplegia (SPG)
|
|
PLP2 |
proteolipid protein 2 |
|
|
|
|
PLPP6 |
phospholipid phosphatase 6 |
|
|
|
|
PNLIPRP1 |
pancreatic lipase related protein 1 |
- Digestion of dietary lipid
|
|
|
|
PPARG |
peroxisome proliferator activated receptor gamma |
- PPARA activates gene expression
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- MECP2 regulates transcription factors
- Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
|
- alpha-Linolenic acid
- Icosapent
- Troglitazone
- Mesalazine
- Valproic acid
- Indomethacin
- Rosiglitazone
- Fenoprofen
- Nateglinide
- Clofazimine
- Repaglinide
- Telmisartan
- Balsalazide
- Ibuprofen
- Glipizide
- Amiodarone
- Pioglitazone
- Mitiglinide
- Bezafibrate
- Flufenamic acid
- Resveratrol
- Phthalic Acid
- Capric acid
- Doconexent
- Oleic Acid
- (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
- 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- Reglitazar
- Elafibranor
- AMG-131
- CLX-0921
- Muraglitazar
- Ertiprotafib
- Ragaglitazar
- Tesaglitazar
- (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
- (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
- 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
- (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
- (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
- (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
- (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
- 9(S)-HODE
- difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
- (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
- 3-(5-methoxy-1H-indol-3-yl)propanoic acid
- Indeglitazar
- (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
- 2-chloro-5-nitro-N-phenylbenzamide
- (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
- 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
- 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
- Triclosan
- (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
- Aleglitazar
- Clinofibrate
- Cannabidiol
- Lobeglitazone
- Ciglitazone
- Dexibuprofen
- Omega-3 fatty acids
- Curcumin
- Arhalofenate
- Isoflavone
- Naveglitazar
- Fenofibric acid
- Fish oil
- Medical Cannabis
- Nabiximols
- Darglitazone
- Curcumin sulfate
|
- Thyroid cancer
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Type II diabetes mellitus
|
|
PPIF |
peptidylprolyl isomerase F |
|
- Cyclosporine
- Proline
- Triglyme
- Coumarin 120
|
|
|
PRKCD |
protein kinase C delta |
- Apoptotic cleavage of cellular proteins
- Calmodulin induced events
- Effects of PIP2 hydrolysis
- SHC1 events in ERBB2 signaling
- DAG and IP3 signaling
- Role of phospholipids in phagocytosis
- G alpha (z) signalling events
- HuR (ELAVL1) binds and stabilizes mRNA
- VEGFR2 mediated cell proliferation
- CLEC7A (Dectin-1) signaling
- RHO GTPases Activate NADPH Oxidases
- Neutrophil degranulation
- Interferon gamma signaling
- KEAP1-NFE2L2 pathway
|
- Tamoxifen
- Staurosporine
- Dequalinium
- 13-Acetylphorbol
- Ingenol mebutate
- Benzoyl peroxide
- Fostamatinib
|
|
|
PSMB4 |
proteasome 20S subunit beta 4 |
- Activation of NF-kappaB in B cells
- Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
- ER-Phagosome pathway
- ER-Phagosome pathway
- Cross-presentation of soluble exogenous antigens (endosomes)
- Autodegradation of Cdh1 by Cdh1:APC/C
- SCF-beta-TrCP mediated degradation of Emi1
- APC/C:Cdc20 mediated degradation of Securin
- APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
- Cdc20:Phospho-APC/C mediated degradation of Cyclin A
- Vpu mediated degradation of CD4
- Vif-mediated degradation of APOBEC3G
- SCF(Skp2)-mediated degradation of p27/p21
- Degradation of beta-catenin by the destruction complex
- Downstream TCR signaling
- Regulation of activated PAK-2p34 by proteasome mediated degradation
- Separation of Sister Chromatids
- FCERI mediated NF-kB activation
- Autodegradation of the E3 ubiquitin ligase COP1
- Regulation of ornithine decarboxylase (ODC)
- ABC-family proteins mediated transport
- AUF1 (hnRNP D0) binds and destabilizes mRNA
- Asymmetric localization of PCP proteins
- Degradation of AXIN
- Degradation of DVL
- Hedgehog ligand biogenesis
- Hh mutants are degraded by ERAD
- Dectin-1 mediated noncanonical NF-kB signaling
- CLEC7A (Dectin-1) signaling
- Degradation of GLI1 by the proteasome
- Degradation of GLI2 by the proteasome
- GLI3 is processed to GLI3R by the proteasome
- Hedgehog 'on' state
- Regulation of RAS by GAPs
- TNFR2 non-canonical NF-kB pathway
- NIK-->noncanonical NF-kB signaling
- Defective CFTR causes cystic fibrosis
- MAPK6/MAPK4 signaling
- UCH proteinases
- Ub-specific processing proteases
- Assembly of the pre-replicative complex
- Orc1 removal from chromatin
- CDK-mediated phosphorylation and removal of Cdc6
- G2/M Checkpoints
- Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
- Ubiquitin-dependent degradation of Cyclin D
- The role of GTSE1 in G2/M progression after G2 checkpoint
- FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- Regulation of RUNX2 expression and activity
- Regulation of RUNX2 expression and activity
- Regulation of RUNX3 expression and activity
- Regulation of PTEN stability and activity
- Neddylation
- Regulation of expression of SLITs and ROBOs
- Interleukin-1 signaling
- Negative regulation of NOTCH4 signaling
- KEAP1-NFE2L2 pathway
- GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
- Degradation of CDH1
- Somitogenesis
- Antigen processing: Ubiquitination & Proteasome degradation
- Proteasome assembly
- Proteasome assembly
- Antigen processing: Ub, ATP-independent proteasomal degradation
- GSK3B-mediated proteasomal degradation of PD-L1(CD274)
- SPOP-mediated proteasomal degradation of PD-L1(CD274)
- AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)
- Degradation of CRY and PER proteins
- Degradation of CRY and PER proteins
- Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide
- Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide
|
- (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE
|
|
|
RFT1 |
RFT1 glycolipid translocator homolog |
- Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
- Defective RFT1 causes CDG-1n
|
|
- Congenital disorders of glycosylation (CDG) type I
|